Company profile: Eagle Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of injectable pharmaceuticals for critical care and oncology, including PEMFEXY (pemetrexed) for nonsquamous NSCLC and malignant pleural mesothelioma; BARHEMSYS (amisulpride) for prevention and treatment of postoperative nausea and vomiting; BYFAVO (remimazolam) for procedural sedation; RYANODEX (dantrolene) for malignant hyperthermia; BELRAPZO and BENDEKA (bendamustine) for CLL and indolent B-cell NHL.
Products and services
- BENDEKA: Oncology-grade bendamustine hydrochloride injection indicated for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma therapy
- BYFAVO: Clinical-grade remimazolam injection utilized for procedural sedation in adults undergoing short procedures, supporting procedural sedation requirements during short procedures
- PEMFEXY: Chemotherapy-grade injectable pemetrexed engineered for combination use with cisplatin to treat non-squamous non-small cell lung cancer and malignant pleural mesothelioma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eagle Pharmaceuticals
InMed Pharmaceuticals
HQ: Canada
Website
- Description: Provider of cannabinoid-based pharmaceutical candidates and rare cannabinoid ingredients. Develops INM-755 (cannabinol topical for epidermolysis bullosa) and INM-088 (cannabinol-based for glaucoma). Through BayMedica, supplies bioidentical rare cannabinoids (CBC, d9-THCV, CBDV, CBTC) for B2B health and wellness. Offers IntegraSyn, combining biosynthesis and chemical synthesis to produce cannabinoids, aiming for high yield and cost efficiency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InMed Pharmaceuticals company profile →
Neutrolis
HQ: United States
Website
- Description: Provider of candidate-stage, first-in-class anti-NET therapies, including the exDNASETM platform to create molecules that disassemble Neutrophil Extracellular Traps; NTR-L303 to resolve hyperinflammation and disrupt NET-immune complexes; NEU-101 for surface inflammation; and NET biomarkers to identify, treat, and monitor responsive patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neutrolis company profile →
ZymoGenetics
HQ: United States
Website
- Description: Provider of therapeutic protein discovery, development, and early manufacturing, supported by fully integrated research and development capabilities in scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, and clinical expertise; with an early focus on production systems for recombinant proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ZymoGenetics company profile →
Matrx Pharmaceuticals
HQ: Poland
Website
- Description: Provider of pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Matrx Pharmaceuticals company profile →
Biosplice
HQ: United States
Website
- Description: Provider of therapeutic solutions and clinical trials for tissue-level regeneration, developing therapies that modulate alternative splicing via CLK/DYRK kinase inhibition to treat diseases like osteoarthritis and cancer. Offerings include Lorecivivint, an injectable small molecule for knee osteoarthritis to reduce pain, improve function, and protect cartilage, with trials evaluating safety, efficacy, and dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biosplice company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eagle Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eagle Pharmaceuticals
2.2 - Growth funds investing in similar companies to Eagle Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eagle Pharmaceuticals
4.2 - Public trading comparable groups for Eagle Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →